Phase II trial of YHI-1003

Phase II trial of YHI-1003 monotherapy in patients with advanced or relapsed gynecologic cancer

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222238

Enrollment

Registered

2013-09-27

Start date

2013-09-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced or relapsed gynecologic cancer (ovarian, endometric or cervical cancer)

Interventions

investigational material(s) Generic name etc : YHI-1003 INN of investigational material : Perifosine Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigationa

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: (1)Patients with a histologically-diagnosed ovarian , endometric or cervical cancer (2)Patients with a history of treatment with platinum-based chemotherary (3)Patients who have agreed with the investigation of biomarkers (4)Patients who can be treated with oral medications (5)Patients with at least one measurable disease

Exclusion criteria

Exclusion criteria: (1)Patients with a history of treatment with PI3K, AKT or mTOR inhibitor (2)Patients with uncontrolled intercurrent illness (3)Patients with brain metastases or suspected brain metastases

Design outcomes

Primary

Measure	Time frame
Disease Control Rate RECIST ver1.1	—

Secondary

Measure	Time frame
efficacy,safety and biomarker RECIST ver1.1, CTCAE v.4.0	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026